RT Journal Article
SR Electronic
T1 Disease burden and clinical severity of the first pandemic wave of COVID-19 in Wuhan, China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.27.20183228
DO 10.1101/2020.08.27.20183228
A1 Yang, Juan
A1 Chen, Xinhua
A1 Deng, Xiaowei
A1 Chen, Zhiyuan
A1 Gong, Hui
A1 Yan, Han
A1 Wu, Qianhui
A1 Shi, Huilin
A1 Lai, Shengjie
A1 Ajelli, Marco
A1 Viboud, Cecile
A1 Yu, Hongjie
YR 2020
UL http://medrxiv.org/content/early/2020/09/01/2020.08.27.20183228.abstract
AB The pandemic of novel coronavirus disease 2019 (COVID-19) began in Wuhan, China, where a first wave of intense community transmission was cut short by interventions. Using multiple data source, we estimated the disease burden and clinical severity of COVID-19 by age in Wuhan from December 1, 2019 to March 31, 2020. We adjusted estimates for sensitivity of laboratory assays and accounted for prospective community screenings and healthcare seeking behaviors. Rates of symptomatic cases, medical consultations, hospitalizations and deaths were estimated at 796 (95%CI: 703-977), 489 (472-509), 370 (358-384), and 36.2 (35.0-37.3) per 100,000 persons, respectively. The COVID-19 outbreak in Wuhan had higher burden than the 2009 influenza pandemic or seasonal influenza, and that clinical severity was similar to that of the 1918 influenza pandemic. Our comparison puts the COVID-19 pandemic into context and could be helpful to guide intervention strategies and preparedness for the potential resurgence of COVID-19.Competing Interest StatementH.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. None of those research funding is related to COVID-19. All other authors report no competing interests.Funding StatementThe study was supported by grants from the National Science Fund for Distinguished Young Scholars (No. 81525023), National Science and Technology Major Project of China (No. 2018ZX10201001-010, No. 2018ZX10713001-007, No. 2017ZX10103009-005).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All these data were in the public domain. All these are aggregated data, only presenting the numbers of cases or proportions/percentages, and thus are robustly anonymized data. Ethical review for the re-use of these secondary data is not normally be required. Accordingly, we do not apply for ethical review to approve the study. I confirmed that this study was not necessary for approval from the IRB of School of Public Health, Fudan University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll aggregated data analyzed in this study are included in the Article and its Supplementary Information files. Individual-level data on confirmed COVID-19 cases as of March 8, 2020 are available on https://github.com/chaolongwang/SAPHIRE, and health seeking behavior survey data are available on GitHub at https://github.com/zychenfd/Wuhan-disease-burden.